Frags2Drugs:一种基于片的新方法,用于发现激酶抑制剂
Gautier Peyrat1, Colin Bournez1, Pascal Krezel1
1Université d'Orléans, CNRS, ICOA, UMR 7311, Orléans, France.
Pharmaceuticals (Basel, Switzerland)
|February 27, 2026
概括
我们开发了Frags2Drugs (F2D),这是一个用于设计新型蛋白激酶抑制剂的in silico工具. 这种基于碎片的药物设计方法有效地生成和过分子,以在ATP结合部位获得最佳的结合亲和力.
科学领域:
- 计算化学是一种计算化学.
- 药物的发现和设计.
背景情况:
- 基于碎片的药物设计 (FBDD) 是药物发现的既定策略.
- 蛋白激酶是治疗干预的关键目标.
研究的目的:
- 为设计新型蛋白激酶抑制剂提出一种创新的in silico FBDD方法.
- 为了介绍Frags2Drugs (F2D) 计算工具.
主要方法:
- 利用由共结晶的连接体衍生的3D碎片库,存储在以图为导向的数据库中.
- 开发了Frags2Drugs (F2D) 工具,通过在目标腔内连接碎片来构建分子.
- 应用分子波器,包括酶抑制剂特异性波器,以优先考虑潜在的候选药物.
主要成果:
- 通过成功重建已知的共同结晶的配体和激酶抑制剂,验证了F2D方法.
- 证明了该工具能够检索现有抑制剂并设计各种蛋白质激酶的新型I型,I1/2型,II型和宏循环抑制剂的能力.
结论:
- 开发了一种基于片的新联体设计工具 (F2D).
- 通过在ATP结合部位内生长分子支架,F2D可以有效地识别新型激酶抑制剂.
相关概念视频
Drug Discovery: Overview
12.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.3K
Protein-protein Interfaces
14.9K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.9K


